Doxycycline postexposure prophylaxis (Doxy-PEP) has emerged as a key strategy to reduce bacterial sexually transmitted infections (STIs), including chlamydia, gonorrhea, and syphilis. The U.S. Centers for Disease Control and Prevention (CDC) now recommends Doxy-PEP for men who have sex with men (MSM) and transgender women with a history of at least one STI in the past 12 months.
Clinical trials, such as the DoxyPEP study published in the New England Journal of Medicine in 2023, showed that taking 200 mg of doxycycline within 72 hours of condomless sex reduced STI incidence by 65% overall. Specifically, chlamydia and syphilis cases dropped by about 70%, and gonorrhea by about 55%.
The CDC's 2024 guidelines highlight Doxy-PEP as a safe and effective prevention tool, though concerns about antibiotic resistance and gut microbiome disruption remain under study. The Society of Infectious Diseases Pharmacists (SIDP) has endorsed the approach, emphasizing its role in high-risk populations.
As of May 2026, Doxy-PEP is increasingly adopted in sexual health clinics across the U.S., with ongoing research into its long-term impact on antimicrobial resistance. Public health officials stress that Doxy-PEP should complement, not replace, regular STI testing and condom use.
